ALK-Abelló A/S (AKBLF)
OTCMKTS · Delayed Price · Currency is USD
35.80
-0.30 (-0.83%)
At close: Jan 26, 2026
ALK-Abelló Revenue
ALK-Abelló had revenue of 1.53B DKK in the quarter ending September 30, 2025, with 16.53% growth. This brings the company's revenue in the last twelve months to 6.08B, up 12.91% year-over-year. In the year 2024, ALK-Abelló had annual revenue of 5.54B with 14.78% growth.
Revenue (ttm)
6.08B DKK
Revenue Growth
+12.91%
P/S Ratio
7.84
Revenue / Employee
2.20M DKK
Employees
2,764
Market Cap
7.49B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.54B | 713.00M | 14.78% |
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | 3.49B | 217.00M | 6.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
ALK-Abelló News
- 13 days ago - ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children - GlobeNewsWire
- 3 months ago - Q3 2025 ALK-Abello A/S Earnings Call Transcript - GuruFocus
- 3 months ago - ALK-Abelló A/S (AKBLF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ALK-Abelló A/S 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - ALK-Abelló A/S (AKBLF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - ALK-Abelló A/S 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - ALK-Abelló A/S gives Q2 results - Seeking Alpha
- 9 months ago - ALK-Abelló A/S (AKBLF) Q1 2025 Earnings Call Transcript - Seeking Alpha